HK1053115A1 - Quinazoline derivatives for the treatment of tumours. - Google Patents

Quinazoline derivatives for the treatment of tumours.

Info

Publication number
HK1053115A1
HK1053115A1 HK03105395A HK03105395A HK1053115A1 HK 1053115 A1 HK1053115 A1 HK 1053115A1 HK 03105395 A HK03105395 A HK 03105395A HK 03105395 A HK03105395 A HK 03105395A HK 1053115 A1 HK1053115 A1 HK 1053115A1
Authority
HK
Hong Kong
Prior art keywords
sup
treatment
quinazoline derivatives
tumours
containment
Prior art date
Application number
HK03105395A
Inventor
Laurent Francois And Hennequin
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27223613&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1053115(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1053115A1 publication Critical patent/HK1053115A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The invention concerns quinazoline derivatives of Formula (I) wherein each of Q<SUP>1</SUP>, Z, m, R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3 </SUP>and Q<SUP>2 </SUP>have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease
HK03105395A 2000-06-06 2003-07-25 Quinazoline derivatives for the treatment of tumours. HK1053115A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00401581 2000-06-06
EP01400297 2001-02-07
EP01400565 2001-03-05
PCT/GB2001/002424 WO2001094341A1 (en) 2000-06-06 2001-06-01 Quinazoline derivatives for the treatment of tumours

Publications (1)

Publication Number Publication Date
HK1053115A1 true HK1053115A1 (en) 2003-10-10

Family

ID=27223613

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105395A HK1053115A1 (en) 2000-06-06 2003-07-25 Quinazoline derivatives for the treatment of tumours.

Country Status (32)

Country Link
US (3) US7049438B2 (en)
EP (1) EP1292594B1 (en)
JP (1) JP3774438B2 (en)
KR (2) KR100807162B1 (en)
CN (1) CN100345844C (en)
AR (1) AR030937A1 (en)
AT (1) ATE275145T1 (en)
AU (2) AU2001260482B2 (en)
BG (1) BG65836B1 (en)
BR (1) BR0111335A (en)
CA (1) CA2407371C (en)
CO (1) CO5700751A2 (en)
CZ (1) CZ301987B6 (en)
DE (1) DE60105295T2 (en)
DK (1) DK1292594T3 (en)
EE (1) EE05481B1 (en)
ES (1) ES2225545T3 (en)
HK (1) HK1053115A1 (en)
HU (1) HU229290B1 (en)
IL (2) IL152754A0 (en)
IS (1) IS2114B (en)
MX (1) MXPA02011765A (en)
MY (1) MY127369A (en)
NO (1) NO324838B1 (en)
NZ (1) NZ522204A (en)
PL (1) PL210852B1 (en)
PT (1) PT1292594E (en)
SI (1) SI1292594T1 (en)
SK (1) SK286748B6 (en)
TW (1) TWI288748B (en)
UA (1) UA73993C2 (en)
WO (1) WO2001094341A1 (en)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100821446B1 (en) 2000-08-21 2008-04-10 아스트라제네카 아베 Quinazoline derivatives
US6939866B2 (en) 2000-10-13 2005-09-06 Astrazeneca Ab Quinazoline derivatives
JP2004511479A (en) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ Quinazoline derivatives
JP4564713B2 (en) 2000-11-01 2010-10-20 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Nitrogen heterocyclic compounds, and methods for making nitrogen heterocyclic compounds and intermediates thereof
AU2002245709A1 (en) * 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
PT1370553E (en) * 2001-03-23 2006-09-29 Bayer Corp RHOQUINASE INHIBITORS
ES2312557T3 (en) 2001-04-19 2009-03-01 Astrazeneca Ab DERIVATIVES OF QUINAZOLINA.
DE60215178T2 (en) 2001-07-16 2007-08-23 Astrazeneca Ab QUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF TYROSINE KINASE
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
KR20050042055A (en) * 2001-11-03 2005-05-04 아스트라제네카 아베 Quinazoline derivaives as antitumor agents
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
AU2002365664A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives as antitumour agents
US7268230B2 (en) * 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
ATE429230T1 (en) 2002-07-09 2009-05-15 Astrazeneca Ab CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
BR0315756A (en) * 2002-11-04 2005-09-06 Astrazeneca Ab Quinazoline derivative or a pharmaceutically acceptable salt thereof, process for the preparation thereof, pharmaceutical composition, use of said derivative or a pharmaceutically acceptable salt thereof, and method for producing an anti-invasive effect by arresting and / or treating solid tumor disease in a warm-blooded animal requiring such treatment
AU2003290279A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab Quinazoline derivatives
WO2004056812A1 (en) * 2002-12-23 2004-07-08 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
MXPA06002964A (en) * 2003-09-16 2006-06-14 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors.
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
ES2374553T3 (en) 2004-05-06 2012-02-17 Warner-Lambert Company Llc 4-PHENYLAMINE-QUINAZOLIN-6-IL-AMIDAS.
GB0412074D0 (en) 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
EP1756088A1 (en) * 2004-06-04 2007-02-28 AstraZeneca AB Quinazoline derivatives as erbb receptor tyrosine kinases
UY29198A1 (en) * 2004-11-09 2006-05-31 Cancer Rec Tech Ltd SUBSTITUTED DERIVATIVES OF QUINAZOLINONA AND REPLACED DERIVATIVES OF QUINAZOLINA-2, 4-DIONA, COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
EP1838712B8 (en) * 2004-12-14 2011-10-12 AstraZeneca AB Pyrazolopyrimidine compounds as antitumor agents
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc Compounds and therapeutical use thereof
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
CN1854130B (en) * 2005-04-15 2011-04-20 中国医学科学院药物研究所 Chinazoline derivative, its production, medicinal composition and use
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
JP2009517450A (en) 2005-12-02 2009-04-30 アストラゼネカ アクチボラグ 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
JP2009517451A (en) * 2005-12-02 2009-04-30 アストラゼネカ アクチボラグ Quinazoline derivatives used as inhibitors of ERBB tyrosine kinase
UY30183A1 (en) 2006-03-02 2007-10-31 Astrazeneca Ab QUINOLINE DERIVATIVES
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
US7858782B2 (en) 2006-12-15 2010-12-28 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
EP2117544A4 (en) * 2006-12-19 2010-03-03 Univ Texas Biomarker identifying the reactivation of stat3 after src inhibition
EA200901041A1 (en) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх BICYCLIC HETEROCYCLES CONTAINING THESE COMPOUNDS MEDICINES, THEIR APPLICATION AND METHOD OF OBTAINING THEM
US8044056B2 (en) 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
TWI453021B (en) 2007-10-11 2014-09-21 Astrazeneca Ab Novel protein kinase b inhibitors
MY150054A (en) 2007-10-29 2013-11-29 Natco Pharma Ltd Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
EA019709B1 (en) 2008-02-07 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Spirocyclic heterocycles and use thereof as medicaments
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
EP2303276B1 (en) 2008-05-13 2013-11-13 AstraZeneca AB Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US9256904B1 (en) 2008-08-14 2016-02-09 Experian Information Solutions, Inc. Multi-bureau credit file freeze and unfreeze
US20100069340A1 (en) * 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
WO2010032060A1 (en) 2008-09-19 2010-03-25 Medimmune Llc Antibodies directed to dll4 and uses thereof
CN101723906B (en) * 2008-10-10 2011-09-28 山西仁源堂药业有限公司 Compound, medical composition containing same as well as preparation method and application
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
JP2012513194A (en) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ Targeted binding agents directed to α5β1 and uses thereof
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
AU2010212590B2 (en) 2009-02-10 2013-01-10 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
GB0905127D0 (en) 2009-03-25 2009-05-06 Pharminox Ltd Novel prodrugs
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
CN102573484B (en) 2009-06-09 2015-07-01 加利福尼亚资本权益有限责任公司 Benzyl substituted triazine derivatives and their therapeutical applications
CN102573480B (en) 2009-06-09 2015-06-10 加利福尼亚资本权益有限责任公司 Triazine derivatives and their therapeutical applications
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
KR20120113709A (en) 2009-11-18 2012-10-15 아스트라제네카 아베 Benzoimidazole compounds and uses thereof
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
EP2507237A1 (en) 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2011085641A1 (en) 2010-01-15 2011-07-21 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
JP2013517321A (en) 2010-01-19 2013-05-16 アストラゼネカ アクチボラグ Pyrazine derivative
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
SA111320519B1 (en) 2010-06-11 2014-07-02 Astrazeneca Ab Pyrimidinyl Compounds for Use as ATR Inhibitors
TWI535712B (en) 2010-08-06 2016-06-01 阿斯特捷利康公司 Chemical compounds
CN102656179B (en) 2010-08-28 2015-07-29 苏州润新生物科技有限公司 Bufalin derivative, its pharmaceutical composition and purposes
GB201016442D0 (en) 2010-09-30 2010-11-17 Pharminox Ltd Novel acridine derivatives
WO2012067268A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
EA024026B1 (en) 2010-11-25 2016-08-31 Рациофарм Гмбх Novel salts and polymorphic forms of afatinib
EP3453714B1 (en) 2011-02-02 2020-11-04 Suzhou Neupharma Co., Ltd Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof
AU2012216893B2 (en) 2011-02-17 2016-08-11 Cancer Therapeutics Crc Pty Limited FAK inhibitors
AU2012216894B2 (en) 2011-02-17 2016-07-14 Cancer Therapeutics Crc Pty Limited Selective FAK inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US8530470B2 (en) 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
CN103702990B (en) 2011-07-27 2015-09-09 阿斯利康(瑞典)有限公司 2-(2,4,5-substituted aniline) pyrimidine derivatives is used for the treatment of cancer as EGFR modulator
CN107245056A (en) 2011-08-26 2017-10-13 润新生物公司 Chemical entities, composition and method
EP3332785B1 (en) 2011-09-14 2020-05-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2757885B1 (en) 2011-09-21 2017-03-15 Neupharma, Inc. Certain chemical entites, compositions, and methods
EP2760458B1 (en) 2011-09-29 2017-06-14 The University of Liverpool Prevention and/or treatment of cancer and/or cancer metastasis
US9249111B2 (en) 2011-09-30 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-RAF kinase inhibitors
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
EP2806874B1 (en) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
EP3453713B1 (en) 2012-04-29 2021-09-08 Neupharma, Inc. Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer
GB201211021D0 (en) 2012-06-21 2012-08-01 Cancer Rec Tech Ltd Pharmaceutically active compounds
WO2014026243A1 (en) 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
CN104812389B (en) 2012-09-24 2020-07-17 润新生物公司 Certain chemical entities, compositions, and methods
WO2014075077A1 (en) 2012-11-12 2014-05-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
RU2656593C2 (en) 2013-01-31 2018-06-06 Неомед Инститьют Imidazopyridine compounds useful in treatment of condition associated with p2x3 and/or p2x2/3 activity
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP3763710A1 (en) 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9937137B2 (en) 2013-03-15 2018-04-10 Neurocentria, Inc. Magnesium compositions and uses thereof for cancers
AR095443A1 (en) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii HEREROCICLES CONDENSED WITH ACTION ON ATR
WO2014195507A1 (en) 2013-06-07 2014-12-11 Universite Catholique De Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
CN111285813A (en) 2013-08-23 2020-06-16 润新生物公司 Chemical entities, compositions, and methods
WO2015066482A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN105916506B (en) 2013-11-20 2020-01-07 圣诺康生命科学公司 Quinazoline derivatives as inhibitors of TAM family kinases
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
CN108064274A (en) 2014-07-30 2018-05-22 耶达研究及发展有限公司 For cultivating the culture medium of multipotential stem cell
MA41179A (en) 2014-12-19 2017-10-24 Cancer Research Tech Ltd PARG INHIBITOR COMPOUNDS
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
WO2016130897A1 (en) 2015-02-13 2016-08-18 Yu Paul B Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
CA2994023A1 (en) 2015-08-04 2017-02-02 University Of South Australia N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
AU2017221268B2 (en) 2016-02-15 2024-02-15 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib
WO2017178845A1 (en) 2016-04-15 2017-10-19 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
CN107459519A (en) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 Annelated pyrimidines piperidines ring derivatives and its preparation method and application
KR101706346B1 (en) 2016-06-09 2017-03-13 서동균 Fixing device for a out side panel of building
EP4006035B1 (en) 2016-08-15 2023-11-22 Neupharma, Inc. Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN109688818A (en) 2016-09-08 2019-04-26 卡拉制药公司 Crystal form of therapeutic compounds and application thereof
CN110036006B (en) 2016-09-22 2022-12-13 癌症研究科技有限公司 Preparation and use of pyrimidinone derivatives
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
US10287253B2 (en) 2016-12-05 2019-05-14 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
JP7113528B2 (en) 2017-02-01 2022-08-05 オーセントラ セラピュティクス ピーティーワイ エルティーディー N-Cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine derivatives as therapeutic agents
GB201704325D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
WO2018215798A1 (en) 2017-05-26 2018-11-29 Cancer Research Technology Limited 2-quinolone derived inhibitors of bcl6
WO2019007447A1 (en) 2017-07-05 2019-01-10 E.P.O.S Iasis Research And Development Limited Multifunctional conjugates
CA3070903A1 (en) 2017-08-18 2019-02-21 Cancer Research Technology Limited Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
CN107987064A (en) * 2017-12-30 2018-05-04 王兆举 A kind of preparation method for the medicine saracatinib for treating osteocarcinoma
CN107814793A (en) * 2017-12-30 2018-03-20 胡张艳 A kind of preparation method of small molecule Src tyrosine kinase inhibitors saracatinib and its intermediate
US11325900B2 (en) 2018-01-15 2022-05-10 Aucentra Holdings Pty Ltd 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
KR20200143361A (en) 2018-02-08 2020-12-23 뉴파마, 인크. Certain Chemical Substances, Compositions, and Methods
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
CN110357858B (en) 2018-04-09 2022-02-18 威尚（上海）生物医药有限公司 5-substituted difluoropiperidine compounds having blood-brain barrier crossing capability
WO2019196622A1 (en) * 2018-04-09 2019-10-17 威尚（上海）生物医药有限公司 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
BR112020020832A2 (en) 2018-04-13 2021-01-19 Cancer Research Technology Limited BCL6 INHIBITORS
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
TW202003475A (en) 2018-06-04 2020-01-16 美商亞博創新醫藥有限公司 Pyrimidine compounds containing acidic groups
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
EP3914698A1 (en) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
CN113811296A (en) 2019-02-27 2021-12-17 阿斯利康(瑞典)有限公司 Methods of treating fibrotic diseases or disorders or interstitial lung disease with SRC kinase inhibitors
WO2020201773A1 (en) 2019-04-05 2020-10-08 Storm Therapeutics Ltd Mettl3 inhibitory compounds
GB201905328D0 (en) 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
GB201908885D0 (en) 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds
JP2022545930A (en) 2019-08-31 2022-11-01 上海奕拓醫藥科技有限責任公司 Pyrazole derivative as FGFR inhibitor and method for preparing the same
MX2022003276A (en) 2019-09-20 2022-04-11 Ideaya Biosciences Inc 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors.
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
CN115151540A (en) 2019-12-02 2022-10-04 风暴治疗有限公司 Polyheterocyclic compounds as METTL3 inhibitors
GB202004960D0 (en) 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
GB202008201D0 (en) 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
GB202012482D0 (en) 2020-08-11 2020-09-23 Univ Of Huddersfield Novel compounds and therapeutic uses thereof
GB202012969D0 (en) 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
US20230391770A1 (en) 2020-10-06 2023-12-07 Storm Therapeutics Limited Mettl3 inhibitory compounds
WO2022074391A1 (en) 2020-10-08 2022-04-14 Storm Therapeutics Limited Compounds inhibitors of mettl3
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
IL308518A (en) 2021-05-17 2024-01-01 Hk Inno N Corp Benzamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
GB202107907D0 (en) 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
GB202108383D0 (en) 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
GB202110373D0 (en) 2021-07-19 2021-09-01 Neophore Ltd Inhibitor compounds
WO2023057394A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
WO2023057389A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag Parg inhibitory compounds
GB202117224D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Inhibitor compounds
GB202117225D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Protac compounds
GB202202006D0 (en) 2022-02-15 2022-03-30 Chancellor Masters And Scholars Of The Univ Of Oxford Anti-cancer treatment
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
GB202204935D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd Nanoparticles
WO2023218201A1 (en) 2022-05-11 2023-11-16 Cancer Research Technology Limited Ikk inhibitors
GB202209404D0 (en) 2022-06-27 2022-08-10 Univ Of Sussex Compounds
WO2024030825A1 (en) 2022-08-01 2024-02-08 Neupharma, Inc Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs
GB202213167D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024074497A1 (en) 2022-10-03 2024-04-11 Forx Therapeutics Ag Parg inhibitory compound

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5411963A (en) * 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (en) * 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
KR100225721B1 (en) 1994-02-23 1999-10-15 디. 제이. 우드, 스피겔 알렌 제이 4-heterocyclyl-substitute quinazoline derivatives, processes for their preparation and their use as anti-cancer agents.
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (en) 1994-11-12 1997-12-01 Zeneca Ltd
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
DE69716916T2 (en) 1996-07-13 2003-07-03 Glaxo Group Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
AR012634A1 (en) 1997-05-02 2000-11-08 Sugen Inc QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
BR9910025A (en) * 1998-04-29 2000-12-26 Pfizer Prod Inc N- (3-Ethinylphenylamino) -6,7-bis (2-methoxyethoxy) -4-quinazo linamine dehydrated and monohydrated mesylate
HUP0102793A3 (en) * 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
CA2337999A1 (en) 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
HUP0103386A3 (en) 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
PT1117653E (en) 1998-10-01 2003-06-30 Astrazeneca Ab QUINOLINE AND QUINAZOLINE DERIVATIVES AND THEIR USE AS CYTOSINE MEDIUM-INHIBITORS
WO2000021955A1 (en) 1998-10-08 2000-04-20 Astrazeneca Ab Quinazoline derivatives
GEP20032997B (en) * 1998-11-19 2003-06-25 Warner Lambert Co N-[4-(3-Chloro-4-Fluoro-Phenylamino)-7-(3-Morpholin-4-Yl-Propoxy)-Quinazolin-6-Yl]-crylamide, as an Irreversible Inhibitor of Tyrosine Kinases
PT1154774E (en) 1999-02-10 2005-10-31 Astrazeneca Ab QUINAZOLINE DERIVATIVES AS ANGIOGENESE INHIBITORS
PL351619A1 (en) 1999-02-27 2003-05-19 Boehringer Ingelheim Pharma 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911509A1 (en) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US6411963B1 (en) * 1999-07-09 2002-06-25 Junot Systems, Inc. External system interface method and system
KR20020032608A (en) 1999-09-21 2002-05-03 다비드 에 질레스 Quinazoline compounds and pharmaceutical compositions containing them
DE60043349D1 (en) 1999-09-21 2009-12-31 Astrazeneca Ab CHINAZOLIN DERIVATIVES AND THEIR USE AS DRUGS
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
ES2267748T3 (en) 2000-04-07 2007-03-16 Astrazeneca Ab QUINAZOLINE COMPOUNDS.
KR100821446B1 (en) 2000-08-21 2008-04-10 아스트라제네카 아베 Quinazoline derivatives

Also Published As

Publication number Publication date
EP1292594B1 (en) 2004-09-01
BG65836B1 (en) 2010-02-26
ATE275145T1 (en) 2004-09-15
CA2407371A1 (en) 2001-12-13
MY127369A (en) 2006-11-30
HU229290B1 (en) 2013-10-28
DK1292594T3 (en) 2004-12-06
US20100280042A1 (en) 2010-11-04
EP1292594A1 (en) 2003-03-19
NO20025792L (en) 2002-12-02
CN100345844C (en) 2007-10-31
AU2001260482B2 (en) 2005-06-09
US20060258642A1 (en) 2006-11-16
UA73993C2 (en) 2005-10-17
CN1434821A (en) 2003-08-06
ES2225545T3 (en) 2005-03-16
HUP0301046A3 (en) 2008-12-29
CZ301987B6 (en) 2010-08-25
IS6647A (en) 2002-12-02
PL210852B1 (en) 2012-03-30
DE60105295D1 (en) 2004-10-07
MXPA02011765A (en) 2003-04-10
BG107332A (en) 2003-07-31
US20040214841A1 (en) 2004-10-28
NZ522204A (en) 2004-07-30
KR20030007859A (en) 2003-01-23
PL360745A1 (en) 2004-09-20
IS2114B (en) 2006-06-15
SK286748B6 (en) 2009-04-06
KR100807162B1 (en) 2008-02-27
IL152754A0 (en) 2003-06-24
CZ20023961A3 (en) 2003-03-12
SK17022002A3 (en) 2003-05-02
US7696214B2 (en) 2010-04-13
DE60105295T2 (en) 2005-09-15
US7049438B2 (en) 2006-05-23
SI1292594T1 (en) 2005-02-28
AU6048201A (en) 2001-12-17
TWI288748B (en) 2007-10-21
PT1292594E (en) 2004-12-31
CO5700751A2 (en) 2006-11-30
CA2407371C (en) 2009-10-20
KR20080015055A (en) 2008-02-15
NO324838B1 (en) 2007-12-17
IL152754A (en) 2010-05-31
WO2001094341A1 (en) 2001-12-13
AR030937A1 (en) 2003-09-03
JP2003535859A (en) 2003-12-02
JP3774438B2 (en) 2006-05-17
WO2001094341A9 (en) 2003-04-17
EE200200673A (en) 2004-06-15
NO20025792D0 (en) 2002-12-02
BR0111335A (en) 2003-06-10
HUP0301046A2 (en) 2003-08-28
EE05481B1 (en) 2011-10-17

Similar Documents

Publication Publication Date Title
HK1053115A1 (en) Quinazoline derivatives for the treatment of tumours.
MY129809A (en) Quinazoline derivatives
DE60229046D1 (en) CHINAZOLINE DERIVATIVES
HK1063185A1 (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
DE60116761D1 (en) Adamantanderivate
HK1091486A1 (en) Quinazoline derivatives
HK1048990A1 (en) Novel compounds.
PL366198A1 (en) Novel compounds
HK1057752A1 (en) N-phenyl-2-pyrimidine-amine derivatives
ATE293995T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THAT PROMOTE DRUG ABSORPTION
HUP0204399A3 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
ZA200110540B (en) Novel diphenyl-piperidine derivate.
IL131407A0 (en) Tetrahydropyrido compounds medicaments containing the same and the use thereof
WO2003053960A3 (en) Quinline derivates and their use as mek inhibitors
AU2003281193A1 (en) Quinazoline derivatives for use in the treatment of cancer
TW200420567A (en) Quinazoline derivatives
EP1208840A3 (en) Combination of fluorouracil and a methylol transfer agent for the treatment of tumor metastases and cancer
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
TW200602329A (en) Novel diazine derivatives, their manufacture and use as pharmaceutical agents
MXPA05011671A (en) Novel aniline derivatives, their manufacture and use as pharmaceutical agents.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160601